内镜下右旋糖酐/透明质酸注射治疗儿童高级别膀胱输尿管反流的长期疗效
该研究纳入851例高级别膀胱输尿管反流患儿(共1,287个反流单元,其中IV级1,153条、V级134条),接受内镜下右旋糖酐/透明质酸注射作为一线治疗,中位随访8.5年。首次注射后总缓解率为69.5%,重复注射可进一步提高缓解率,未见明显术后并发症,无患者需行输尿管再植术。
要点
- 高级别反流首次注射缓解率69.5%,IV级70.4%、V级61.9%
- 第二次注射后20.1%缓解,第三次注射后10.4%缓解
- 1岁以下及存在肾瘢痕者首次治疗后持续反流更常见
核心结论
- 内镜下右旋糖酐/透明质酸注射是IV级和V级膀胱输尿管反流有效且安全的长期治疗方法,治疗失败者可重复注射且后续缓解率高。
研究设计与样本
- 回顾性单中心研究,纳入851例(518例女孩、333例男孩)高级别膀胱输尿管反流患儿,中位年龄2.3岁(范围2个月至13.7岁),共1,287个反流单元。
主要发现
- 首次注射后总缓解率为69.5%(895/1,287),IV级缓解率70.4%,V级61.9%。
- 第二次注射后259例(20.1%)缓解,第三次注射后133例(10.4%)缓解。
- 1岁以下及存在肾瘢痕的患者首次治疗后持续反流更常见。
- 未见明显术后并发症,无患者需行输尿管再植术。
- 反流缓解后43例(5.1%)发生发热性尿路感染,其中24例(55.8%)在第一年、15例(34.9%)在第二年、4例(9.3%)在第三年或以后;6例反流复发,8例新发对侧III级反流,均经单次注射成功治疗。
关键数值与推荐
- 反流级别:IV级1,153条输尿管(89.6%),V级134条(10.4%)。
- 99mTc-DMSA闪烁显像发现317例(37.3%)肾瘢痕。
- 中位随访8.5年(范围6个月至16年)。
临床怎么用
- 对于高级别(IV–V级)膀胱输尿管反流患儿,可将内镜下右旋糖酐/透明质酸注射作为一线治疗选择。
- 治疗失败者可重复注射,仍可获得较高缓解率,无需立即行输尿管再植术。
- 对1岁以下及存在肾瘢痕的患儿应加强随访,因其首次治疗后持续反流风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Endoscopic injection of dextranomer/hyaluronic acid is widely acknowledged as first line treatment of lower grade vesicoureteral reflux. We demonstrate its long-term efficacy and safety in eradicating high grade reflux. MATERIALS AND METHODS: A total of 518 girls and 333 boys with a median age of 2.3 years (range 2 months to 13.7 years) underwent endoscopic correction of high grade vesicoureteral reflux using dextranomer/hyaluronic acid. Reflux was unilateral in 415 cases and bilateral in 436, comprising 1,287 refluxing units. Reflux was grade IV in 1,153 ureters (89.6%) and grade V in 134 (10.4%). 99mTechnetium-dimercaptosuccinic acid scintigraphy identified renal scarring in 317 patients (37.3%). Followup ultrasound and voiding cystourethrogram were performed 3 months after intervention and renal ultrasound yearly thereafter. Median followup was 8.5 years (range 6 months to 16 years). RESULTS: Overall resolution rate after the first endoscopic injection was 69.5% (895 of 1,287 cases), with resolution in 70.4% of grade IV and 61.9% of grade V cases. Reflux resolved after a second injection in 259 cases (20.1%) and after a third injection in 133 (10.4%). Persistent reflux after initial treatment was significantly more common in patients younger than age 1 year and in individuals with renal scarring. No significant postoperative complications were observed and no patient required ureteral reimplantation. Following reflux resolution febrile urinary tract infection developed in 43 children (5.1%), including 24 (55.8%) during the first year, 15 (34.9%) during the second year and 4 (9.3%) during year 3 or later. Of these patients 6 had reflux recurrence and 8 had neocontralateral grade III reflux, which was successfully treated with a single endoscopic injection of dextranomer/hyaluronic acid. CONCLUSIONS: Endoscopic injection of dextranomer/hyaluronic acid is an efficient and safe long-term treatment for grade IV and V vesicoureteral reflux, and can easily be repeated in patients with treatment failure with a high subsequent resolution rate.
引用
- Friedmacher F, Colhoun E, Puri P, et al. Endoscopic Injection of Dextranomer/Hyaluronic Acid as First Line Treatment in 851 Consecutive Children with High Grade Vesicoureteral Reflux: Efficacy and Long-Term Results. J Urol. 2018. PMID: 29551405. doi:10.1016/j.juro.2018.03.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。